Navigation Links
Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
Date:1/9/2014

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ --  Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis.  Topline results are expected in to be available in March or early April. 

(Logo:  http://photos.prnewswire.com/prnh/20140109/DA43446LOGO)

"Positive ZA201 results will validate the entire Zoenasa platform, so we are pleased to have achieved this milestone," commented Dennis Schafer, President and CEO of Altheus. "We look forward to gaining alignment on our registration program with the FDA and other Health Authorities as the next step to making Zoenasa available to IBD patients."

Nearly 1.2 million Americans suffer from inflammatory bowel disease. The two most common forms, ulcerative colitis and Crohn's disease, are chronic lifelong conditions which significantly impact quality of life. Front-line treatment for ulcerative colitis is monotherapy with oral or rectal mesalamine.  However, many patients do not achieve symptomatic or endoscopic remission and must escalate to more expensive and risky treatments.   

Zoenasa is a patented, novel combination of two FDA-approved drugs, with well-established efficacy and safety records, that have been shown to act synergistically to improve the signs and symptoms of ulcerative colitis.  In animal models of colitis, Zoenasa resolved inflammation more rapidly and completely than mesalamine (the current front line standard of care). 

Zoenasa Rectal Gel is being investigated for the treatment of left-sided ulcerative colitis, which affects approximately 80% of ulcerative colitis patients.  The U.S. Food and Drug Administration also granted Zoenasa orphan designation for the treatment of pediatric ulcerative colitis.  An oral formulation of Zoenasa is in pre-clinical development.

About ZA201
The ZA201 clinical trial is a 6-week, double-blind, active-controlled Phase 2 study of the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine standard enema therapy in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. http://clinicaltrials.gov/ct2/show/NCT01586533.

About Altheus Therapeutics
Founded in 2007, Altheus Therapeutics, Inc., of Oklahoma City, OK, is a pharmaceutical development company focused on innovative therapies for the treatment of inflammatory bowel disease. http://altheustherapeutics.com.

Contact: Dennis Schafer, CEO
dschafer@altheustherapeutics.com
(405) 319-8180


'/>"/>
SOURCE Altheus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
4. G1 Therapeutics to Present at Biotech Showcase 2014
5. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
6. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
7. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
8. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
9. Dr. Seth Rudnick Joins G1 Therapeutics as Executive Chairman
10. Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance
11. Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):